EyePoint to halve workforce after experimental drug fails second late-stage trial

By Reuters News

Oct 19 (Reuters) - EyePoint EYPT.O on Monday said it would cut about 53% of its workforce and stop studies of its experimental drug for an age-related vision disease after a second late-stage trial failed.

Its shares tanked more than 75% in premarket trading.

  • The trial tested EyePoint's Duravyu against Regeneron's REGN.O blockbuster eye medicine Eylea in patients with wet age-related macular degeneration, a leading cause of blindness in older adults

  • While patients given Duravyu showed improved vision, the drug failed to prove as effective as the standard treatment in preserving eyesight, EyePoint said

  • The company had 214 full-time US employees as of February 27, according to a regulatory filing

  • The setback follows a similar failure in August, when Duravyu missed the main goal in an identical late-stage study

  • JonesTrading analyst Debanjana Chatterjee said she does not "see an immediate regulatory path forward in wet AMD despite strong secondary endpoint results," following the failures

  • EyePoint expects reducing the workforce and ending trials to save about $30 million annually, despite roughly $9 million in severance charges

  • It added it would shift focus to developing Duravyu for diabetic macular edema, another retinal disease, with late-stage trial results expected in late 2027

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.